Clinical Applications of Mesenchymal Stem Cells in Chronic Diseases
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Extraordinary progress in understanding several key features of stem cells has been made in the last ten years, including definition of the niche, and identification of signals regulating mobilization and homing as well as partial understanding of the mechanisms controlling self-renewal, commitment, and differentiation. This progress produced invaluable tools for the development of rational cell therapy protocols that have yielded positive results in preclinical models of genetic and acquired diseases and, in several cases, have entered clinical experimentation with positive outcome. Adult mesenchymal stem cells (MSCs) are nonhematopoietic cells with multilineage potential to differentiate into various tissues of mesodermal origin. They can be isolated from bone marrow and other tissues and have the capacity to extensively proliferate in vitro. Moreover, MSCs have also been shown to produce anti-inflammatory molecules which can modulate humoral and cellular immune responses. Considering their regenerative potential and immunoregulatory effect, MSC therapy is a promising tool in the treatment of degenerative, inflammatory, and autoimmune diseases. It is obvious that much work remains to be done to increase our knowledge of the mechanisms regulating development, homeostasis, and tissue repair and thus to provide new tools to implement the efficacy of cell therapy trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“Unfortunately,MSCs have been reported to promote tumor growth [152] andmetastases [153].”
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“The group of Caplan identified the MSCs from BM for the expression of the specific antigen markers CD105 and CD73 [4].”
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Chen, L., Tredget, E. E., Wu, P. Y. G., & Wu, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001886 · Cited by 1,610 · cited 2×
“[9] L.”
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445 · cited 2×
“However, further studies assessed that, following specific molecular cues, MSCs reached the site of injury and allowed the repair of tissues by means of the expression of different trophic factors [8–10].”
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“Unfortunately,MSCs have been reported to promote tumor growth [152] andmetastases [153].”
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Cited by
Baglio, S. R., Rooijers, K., Koppers-Lalic, D., Verweij, F. J., Pérez Lanzón, M., Zini, N., Naaijkens, B., Perut, F., Niessen, H. W. M., Baldini, N., et al. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0116-z · Cited by 765
Hofer, H. R., & Tuan, R. S. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0394-0 · Cited by 360
Marquez-Curtis, L. A., Janowska-Wieczorek, A., McGann, L. E., & Elliott, J. A. W. (2015) · Cryobiology · doi:10.1016/j.cryobiol.2015.07.003 · Cited by 346
“Applications of MSCs for cellular therapy and regenerative medicine have been the subject of numerous reviews [46,65,139,171,186,196,198].”
BackgroundHow to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?
Li, L., Chen, X., Wang, W. E., & Zeng, C. (2016) · Stem Cells International · doi:10.1155/2016/9682757 · Cited by 220
“MSCs are generally described as nonhematopoietic subpopulation of cells with multilineage potential to differentiate into various tissues of mesodermal origin [5].”
Artificial Intelligence in Regenerative Medicine: Applications and Implications
Nosrati, H., & Nosrati, M. (2023) · Biomimetics · doi:10.3390/biomimetics8050442 · Cited by 158
Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts
Zhu, Cheng, M., Yang, Z., Zeng, C., Chen, J., Xie, Y., Luo, S., Zhang, K., Zhou, S.-F., & Lv, N. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s71466 · Cited by 38
“At present, various vectors are available to transduce genes into MSCs, including retroviral, adenoviral, and lentiviral vectors.(16,22,59) Adenoviral vectors are the most commonly used vectors with high titers.”
Background
Metadata
- Authors
- Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-11
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W1982598271
- Cited by
- 105
- References
- 16
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.